Bupropion News and Research

RSS
Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Smokers who try e-cigarettes to quit are younger and more motivated to quit, study finds

Smokers who try e-cigarettes to quit are younger and more motivated to quit, study finds

Eisai submits BELVIQ NDS with Health Canada

Eisai submits BELVIQ NDS with Health Canada

Smokers trying to quit will have better experience with varenicline, study finds

Smokers trying to quit will have better experience with varenicline, study finds

Orexigen reports progress with FDA on faster path to Contrave NDA resubmission

Orexigen reports progress with FDA on faster path to Contrave NDA resubmission

Prevention is better than cure for smoking in young people

Prevention is better than cure for smoking in young people

BCPR, Orexigen partner to accelerate patient enrollment for Contrave obesity Light Study

BCPR, Orexigen partner to accelerate patient enrollment for Contrave obesity Light Study

Behavioural support programme to make TB patients quit smoking receives BUPA Foundation prize

Behavioural support programme to make TB patients quit smoking receives BUPA Foundation prize

FTC votes to approve Watson's acquisition of Actavis

FTC votes to approve Watson's acquisition of Actavis

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

Orexigen Therapeutics reports net loss of $16.7 million for second quarter 2012

New insight into use and awareness of electronic cigarettes

New insight into use and awareness of electronic cigarettes

Genetics can predict success of smoking cessation and need for medications

Genetics can predict success of smoking cessation and need for medications

Orexigen reports net loss of $10.4 million for first quarter 2012

Orexigen reports net loss of $10.4 million for first quarter 2012

March issue of NeuroPerspective reviews therapeutics for ADHD

March issue of NeuroPerspective reviews therapeutics for ADHD

Weight gain or loss may also depend on medicines taken

Weight gain or loss may also depend on medicines taken

New editorial offers clarity on confusing drug and alcohol addiction terminology

New editorial offers clarity on confusing drug and alcohol addiction terminology

First reliable method to predict whether SSRIs work on depressed patients

First reliable method to predict whether SSRIs work on depressed patients

Switching or adding antidepressants does not exacerbate side effects

Switching or adding antidepressants does not exacerbate side effects

Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society

Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society